Biocon Settles with Bayer and Regeneron, Securing Canada Market Entry Date for Aflibercept Biosimilar
LexBlog IP
MARCH 6, 2024
announced it has signed a settlement agreement with Bayer Inc. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. On March 4, Biocon Biologics Ltd. and Regeneron Pharmaceuticals, Inc.
Let's personalize your content